Tirzepatide

Semaglutide, copper peptide (GHK-Cu), and tirzepatide are three innovative compounds with significant therapeutic potential. **Semaglutide**, a GLP-1 receptor agonist, is widely used for type 2 diabetes and obesity, improving glycemic control and promoting weight loss. **Tirzepatide**, a dual GLP-1 and GIP agonist, offers enhanced metabolic benefits, demonstrating superior efficacy in blood sugar regulation and weight reduction in clinical trials. Meanwhile, **GHK-Cu peptide**, a naturally occurring copper complex, supports tissue repair, collagen production, and anti-aging effects, making it popular in dermatology and regenerative medicine. While semaglutide and tirzepatide primarily target metabolic disorders, GHK-Cu focuses on skin health and wound healing. Together, these compounds represent cutting-edge advancements in metabolic and regenerative therapies, with ongoing research expanding their applications.